InvestorsHub Logo

DewDiligence

06/01/22 11:52 AM

#242665 RE: DewDiligence #240504

BMY will_advance Deucravacitinib to_phase-3_in lupus, based on phase-2 data presented at EULAR:

https://www.businesswire.com/news/home/20220531005751/en

Deucravacitinib is under FDA and EMA review in psoriasis; the PDUFA date is 9/10/22 (#msg-166931026).